Peanut allergen powder

United States Nitrile Gloves Market Report 2023: Market to Reach $2.6 Billion by 2030 - Size, Share, Trends Analysis and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 28, 2023
Medical Supplies, Health, Personal protective equipment, Agriculture, Irritant, Safety, Central Association, Blind, Ansell, Peanut allergen powder, Incidence, Healthcare Facilities Accreditation Program, Powder, Disposable product, Patient, Top Glove, USD, Laboratory, Infection, Urbanization, Growth, Hospital, Agrochemical, Fungal infection, PPE

The "U.S. Nitrile Gloves Market Size, Share & Trends Analysis Report By Type (Powdered, Powder-free), By Product (Disposable, Durable Head Protection), By End-use, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "U.S. Nitrile Gloves Market Size, Share & Trends Analysis Report By Type (Powdered, Powder-free), By Product (Disposable, Durable Head Protection), By End-use, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The healthcare sector is experiencing a surge in demand for nitrile gloves, primarily attributed to the growing incidence of infectious diseases and viral outbreaks.
  • Stringent regulatory policies regarding employee safety will likely fuel the demand for nitrile gloves over the forecast period.
  • These gloves are alternatively known as medical-grade gloves, which have been tested to be effective in the aforementioned environments.

Aravax appoints Dr Brett Haumann to Board of Directors

Retrieved on: 
Friday, May 6, 2022
Board, Board of directors, Allergy, Immune system, Senior, GlaxoSmithKline, Director, RSV, COPD, Trial of the century, Asthma, R, Drug, Food, Peanut allergy, GSK, CEO, Therapy, Pharmaceutical industry, Management, Peanut allergen powder

MELBOURNE, Australia, May 6, 2022 /PRNewswire/ -- Aravax, a clinical stage biotechnology company focused on developing the most advanced novel therapy for peanut allergy, which is designed to be safe, effective, and convenient, today announces the appointment of industry executive Dr Brett Haumann as a non-executive director to its Board of Directors.

Key Points: 
  • MELBOURNE, Australia, May 6, 2022 /PRNewswire/ -- Aravax, a clinical stage biotechnology company focused on developing the most advanced novel therapy for peanut allergy, which is designed to be safe, effective, and convenient, today announces the appointment of industry executive Dr Brett Haumann as a non-executive director to its Board of Directors.
  • Dr Haumann is a pharma veteran with leadership experience spanning preclinical discovery, clinical discovery and development, project leadership, alliance management, business development and both executive and non-executive Board of Director roles.
  • "We are pleased to welcome Brett Haumann to the Board of Directors.
  • Dr Haumann currently serves as the Chief Medical Officer of ReViral, a UK-based company developing novel antiviral therapeutics to target Respiratory Syncytial Virus (RSV).

Global Nitrile Gloves Market Trajectory & Analytics Report 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 11, 2021
Medical Supplies, General Health, Health, Infectious Diseases, Chemicals, Plastics, Hospitals, Manufacturing, Other Health, Infection, CAGR, Peanut allergen powder, COVID-19, Growth, Safety, Hospital, Vaccination, Health care, Hand, Nitrile, Government, Personal protective equipment, Pet, Pharmaceutical industry

The "Nitrile Gloves - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nitrile Gloves - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • This segment currently accounts for a 9.6% share of the global Nitrile Gloves market.
  • The market received a considerable push from the COVID-19 outbreak that created exponential demand for nitrile gloves.
  • Disposable nitrile gloves experienced a dramatic incline in global demand amid COVID-19 that grew three-fold in 2020.

Aimmune’s PALISADE-ARC004 Longitudinal Study Showed PALFORZIA® Safety and Efficacy Increased Over Time in Patients with Peanut Allergy

Retrieved on: 
Wednesday, August 4, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, Food allergies, Medical specialties, Arachis, Medicine, Food and drink, Peanut allergy, Peanut allergen powder, Peanut, Placebo-controlled study, Kari Nadeau, Palifermin, PALISADE-ARC004, Aimmune, Nestlé Health Science, PALISADE-ARC004, AIMMUNE, NESTLé HEALTH SCIENCE

The manuscript, titled Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy, was published online.

Key Points: 
  • The manuscript, titled Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy, was published online.
  • Patients who completed the PALISADE trial were eligible to enter the ARC004 open-label follow-on study, which evaluated the long-term efficacy and safety of daily PALFORZIA dosing beyond one year (52 weeks).
  • After two years of daily PALFORZIA treatment, 80.8% of study participants tolerated 2000 mg of peanut protein in the double-blind, placebo-controlled food challenge.
  • PALISADE (Peanut Allergy oral Immunotherapy Study of AR101 for Desensitization) was an international, randomized (3:1), double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy and safety of AR101 in patients with peanut allergy.

European Commission Approves Aimmune’s PALFORZIA® as First-Ever Treatment for Peanut Allergy in the EU

Retrieved on: 
Monday, December 21, 2020
Biotechnology, General Health, FDA, Health, Pharmaceutical, Fabales, Legumes, Rosids, Food allergies, Immunotherapy, Peanut allergen powder, Peanut, Arachis, Ara h 3, Ara h1, PALFORZIA, the PALISADE and ARTEMIS Phase 3 Clinical Trials, Aimmune, Nestlé Health Science

Aimmune Therapeutics, Inc., a Nestl Health Science Company, today announced that the European Commission (EC) has approved PALFORZIA [defatted powder of Arachis hypogaea L., semen (peanuts)] for the treatment of peanut allergy.

Key Points: 
  • Aimmune Therapeutics, Inc., a Nestl Health Science Company, today announced that the European Commission (EC) has approved PALFORZIA [defatted powder of Arachis hypogaea L., semen (peanuts)] for the treatment of peanut allergy.
  • We are grateful for the efforts of the peanut allergy community who contributed to the development program.
  • Todays announcement is a very important step and means that we are closer than ever before to being able to provide an approved treatment for patients with peanut allergy.
  • A treatment option which provides an additional level of protection has long been awaited in the peanut allergy community and so we are thrilled with todays news.

Development of Needle Free Alternatives for Treatment of Anaphylaxis Underway as Aquestive Therapeutics Launches Phase 1 Clinical Trial - ResearchAndMarkets.com

Retrieved on: 
Friday, September 11, 2020
Health, Pharmaceutical, Medical specialties, Immunology, Clinical medicine, RTT, Food allergies, Respiratory diseases, Allergology, Type I hypersensitivity, Anaphylaxis, Peanut allergen powder, Allergy, Epinephrine

Nestle has built a large health science business focused on dietary management and the deal will add Aimmunes's Palforzia to its portfolio.

Key Points: 
  • Nestle has built a large health science business focused on dietary management and the deal will add Aimmunes's Palforzia to its portfolio.
  • Palforzia is the first FDA approved treatment to reduce the frequency and severity of allergic reactions to peanuts in children and teenagers.
  • This has led to interest in the development of needle free alternatives for treatment of anaphylaxis.
  • Aquestive Therapeutics recently launched a phase 1 clinical trial of an epinephrine film that dissolves under the tongue.